By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Verona Pharma 

Suite 21 - Alpha House
100 Borough High Street
London    SE1 1LB  United Kingdom
Phone: 44-0-20-7863-3300 Fax: 44-0-20-7863-3314



Life Sciences

Company News
Verona Pharma (VRP.L)'s VRP700 Did Not Meet Primary Goals In Phase 2a Trial 6/23/2014 10:31:55 AM
Verona Pharma Data Highlighting Synergistic Action Of Novel Dual PDE3/4 Inhibitor RPL554 With Muscarinic Receptor Antagonists And Beta-Adrenoceptor Agonists In Reversing Bronchoconstriction Presented At American Thoracic Society International Conference 5/21/2014 10:53:36 AM
Verona Pharma Release: RPL554 Presentation At The Asthma And COPD Conference, London, 3 April 2014 4/3/2014 2:08:14 PM
Verona Pharma: Results Of Open Offer 3/24/2014 9:31:21 AM
Verona Pharma: - £13 Million Equity Issue, £1 Million Open Offer And Notice Of GM 3/7/2014 8:47:52 AM
Verona Pharma: Post ERS Briefing - 16th September 9/11/2013 10:32:55 AM
Verona Pharma: Clinical Data Presented at ERS 9/10/2013 9:26:01 AM
Verona Pharma Release: Appointment of Richard Bungay as CFO 9/5/2013 9:30:36 AM
Verona Pharma ("Verona Pharma" Or The "Company") Peer-Reviewed Paper Suggests RPL554 With Glycopyrrolate, or Other Muscarinic Receptor Antagonists, Produces Synergistic Bronchodilation 7/1/2013 10:26:52 AM
Verona Pharma Release: First Patient Dosed in Clinical Trial to Further Evaluate Efficacy of VRP700 as a Treatment for Chronic Severe Cough 6/24/2013 9:28:56 AM